Erratum to: Pan-azole-Resistant Candida guilliermondii from a Leukemia Patient's Silent Funguria(Mycopathologia, (2010), 169, (457-459), DOI 10.1007/s11046-010-9278-5);Pan-azole-resistant Candida guilliermondii from a leukemia patient's silent funguria

Mycopathologia

Volumn 169, Issue 6, 2010, Pages 457-459

  Savini, Vincenzo ^a   Catavitello, Chiara ^a   Di Marzio, Ilaria ^a   Masciarelli, Gioviana ^a   Astolfi, Daniela ^a   Balbinot, Andrea ^a   Bianco, Azaira ^a   Pompilio, Arianna ^b   Di Bonaventura, Giovanni ^b   D'Amario, Claudio ^c   D'Antonio, Domenico ^a  

^a SPIRITO SANTO HOSPITAL   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c San Liberatore Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PICHIA GUILLIERMONDII;

EID: 77952671614     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-010-9291-8     Document Type: Erratum

References (10)

1. Della Vittoria A, Arzeni D, Manso E, Scalise G. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob Agents Chemother. 2006; 50: 2719-27.
2. Girmenia C, Pizzarelli G, Cristini F, Barchiesi F, Spreghini E, Scalise G, et al. Candida guilliermondii fungemia in patients with hematologic malignancies. J Clin Microbiol. 2006; 44: 2458-64.
3. Pfaller MA, Diekema DJ, Mendez M, Kibbler C, Erzsebet P, Chang SC, et al. Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol. 2006; 44: 3551-6.
4. Girmenia C, Pizzarelli G, D'Antonio D, Cristini F, Martino P. In vitro susceptibility testing of Geotrichum capitatum: comparison of the E-test, disk diffusion, and Sensititre colorimetric methods with the NCCLS M27-A2 broth microdilution reference method. Antimicrob Agents Chemother. 2003; 47: 3985-8.
5. Castagnola E, Machetti M, Bucci B, Viscoli C. Antifungal prophylaxis with azole derivatives. Clin Microbiol Infect. 2004; 10(Suppl 1): 86-95.
6. Passos XS, Sales WS, Maciel PJ, Costa CR, Miranda KC, Lemos JA, et al. Candida colonization in intensive care unit patients' urine. Mem Inst Oswaldo Cruz. 2005; 100: 925-8.
7. Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN. International fungal surveillance participant group. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J Clin Microbiol. 2003; 41: 78-83.
8. Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia. 2001; 150: 101-15.
9. Chakrabarti A, Chatterjee SS, Rao KL, Zameer MM, Shivaprakash MR, Singhi S, et al. Recent experience with fungaemia: change in species distribution and azole resistance. Scand J Infect Dis. 2009; 41: 275-84.
10. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12, 052 fungal isolates: review of the literature. Rev Iberoam Micol. 2003; 20: 121-36.